Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis

• Published in: Journal of gastroenterology and hepatology 2005-06, Vol.20 (6), p.882-889
• Main Authors: VAN THIEL, DAVID H, FARR, DEBORAH E, MINDIKOGLU, AYSE L, TODO, AKIRA, GEORGE, MAGDALENE M
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Biomarkers - blood; coagulation; coagulopathy; Enzyme-Linked Immunosorbent Assay; Factor VII - therapeutic use; Factor VIIa; Female; fibrinolysis; Gastroenterology. Liver. Pancreas. Abdomen; Hematologic and hematopoietic diseases; Humans; Liver Cirrhosis - blood; Liver Cirrhosis - drug therapy; liver disease; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Other diseases. Semiology; Platelet diseases and coagulopathies; Recombinant Proteins - therapeutic use; Thrombomodulin - blood; Thrombomodulin - drug effects; Thromboplastin - drug effects; Thromboplastin - metabolism; Treatment Outcome
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/j.1440-1746.2005.03761.x

Background:  Recombinant human factor VIIa (rhFVIIa) is used to treat hemophilia and occasionally individuals with liver disease. The aim of the present study was to investigate the consequences of rhFVIIa in individuals with advanced liver disease in an attempt to understand the mechanism of action of rhFVIIa in this unique population. Methods:  Levels of plasma tissue factor, plasminogen activator inhibitor‐1, tissue factor pathway inhibitor, fibrin split products, d‐dimers and free thrombomodulin were measured following the administration of rhFVIIa in 17 subjects. The results were compared to normal controls. Results:  The prothrombin time declined from 20.2 ± 2.8 s to 14.3 ± 3.9 s (P